|Bid||11.79 x 800|
|Ask||11.83 x 2900|
|Day's Range||11.59 - 11.94|
|52 Week Range||11.59 - 27.13|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-27.08%|
|Beta (5Y Monthly)||-9.72|
|Expense Ratio (net)||0.95%|
VANCOUVER , Sept. 13, 2019 /CNW/ - TruTrace Technologies Inc. (CSE: TTT) (OTCQB: TTTSF) ("TruTrace" or the "Company") today announced that it has closed a second tranche (the "Second Tranche") of a non-brokered private placement financing (the "Financing"). The Second Tranche consisted of 840,950 units (each, a "Unit") of the Company at a price of $0.25 per Unit for gross proceeds of $210,237.50 . Each Unit consists of one common share and one non-transferable common share purchase warrant (each, a "Warrant"). Each Warrant entitles the holder to purchase one additional common share at a price of $0.30 per common share for a period of three (3) years from the closing of the Financing. To date, the Company has raised gross proceeds of $720,237.50 from the first tranche of the Financing and the Second Tranche. The Company expects to close a third tranche of the Financing in a timely manner.
OTC: TTTSF) ("TruTrace" or the "Company"), creator of the first fully-integrated blockchain platform that registers and tracks intellectual property for the cannabis industry, and Segra International Corp. ("Segra"), an agriculture technology company, today announced that the two companies have entered into a letter of intent ("LOI") to establish Segra as a primary genetics verification provider for TruTrace. Pursuant to the LOI, Segra will be a lead genetics partner in the Shoppers Drug Mart ("Shoppers") and TruTrace Technologies medical cannabis verification pilot program recently announced at the World Cannabis Congress (the "Pilot Program").
Bond markets rallied as rates plunged, with yields on 30-year Treasury notes dipping to record lows this week. Contrarian investors who believe the gains were overdone may consider some alternative bond-related ...